Monitor for any lock-up waiver or early resale by PIPE investors, which could create near-term selling pressure. The company's pre-revenue status and declining legacy business mean the stock is driven by pipeline milestones rather than fundamentals — watch for IND filing or clinical data catalysts.
Price Chart
Executive Summary
SL Science Holding Ltd's F-1 registration statement (File No. 333-297881) became effective on August 12, 2026, covering the resale of up to 1,040,000 ordinary shares by PIPE investors from a $7.8M PIPE financing that closed alongside the June 2026 business combination with SPAC Horizon Space Acquisition II Corp. This is a routine resale registration that does not raise new capital for the company, but it introduces potential overhang from the registered shares, with lock-up expiration expected in December 2026. The company is a pre-revenue, pre-clinical-stage Taiwanese biomedical firm developing cell therapies, with no FDA approvals or IND filed, and a legacy cosmetics business generating declining revenue.
Key Facts
- F-1 registration became effective on August 12, 2026 (File No. 333-297881)
- Registration covers up to 1,040,000 ordinary shares for resale by PIPE investors
- PIPE financing was $7.8M and closed alongside June 12, 2026 business combination with SPAC Horizon Space Acquisition II Corp
- Company is pre-revenue, pre-clinical-stage, with no FDA approvals or IND filed
- Legacy exosome cosmetics business generated $2.2M in 2025 revenue, down 35% YoY
- Lock-up expiration expected in December 2026 introduces potential overhang
Financial Impact
No new capital raised; potential overhang from up to 1.04M registered shares (lock-up expires Dec 2026)
Risk Factors
- Potential overhang from PIPE share resales after lock-up expiration
- Pre-revenue, pre-clinical-stage with no FDA approvals or IND filed
- Declining legacy cosmetics revenue ($2.2M in 2025, down 35% YoY)
- High cash burn rate with no near-term revenue catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002644 |
| Document: 9999999995-26-002644-index.html | 9999999995-26-002644 |
| Document: 9999999995-26-002644.txt | 9999999995-26-002644 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 26, 2026 today | Press Release | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 1, 2026 25d ago | SC 13D/A | $1.57 | awaiting T+20 | — | $1.23 (−21.66%) |
Aug 13, 2026 10w ago | EFFECT | $2.71 $2.06 | ▼ −23.99% | ▼ −22.24% | $1.23 (−54.61%) |
Jul 31, 2026 12w ago | F-1 | $3.29 $2.73 | ▼ −17.02% | ▼ −18.26% | $1.23 (−62.61%) |
Jul 10, 2026 15w ago | 6-K | $4.73 $2.67 | ▼ −43.55% | ▼ −45.98% | $1.23 (−74.00%) |
Jun 18, 2026 18w ago | 20-F | $4.52 $4.30 | ▼ −4.87% | ▼ −4.72% | $1.23 (−72.79%) |
Jun 17, 2026 18w ago | 3 | $6.38 $4.33 | ▼ −32.13% | ▼ −33.45% | $1.23 (−80.72%) |
Jun 15, 2026 19w ago | 3 | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
Jun 15, 2026 19w ago | 6-K | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers